Grace Therapeutics, Inc. - Form 8-K Summary
Business Context and Reporting Period
Grace Therapeutics, Inc. (GRCE) filed this Current Report on Form 8-K on August 4, 2026, to disclose a material definitive agreement and unregistered sales of equity securities. The company is a Delaware corporation with principal executive offices in Princeton, New Jersey.
Key Financial Metrics and Transaction Details
- Transaction Type: Private Placement Offering of Common Stock.
- Shares Issued: 4,761,904 shares.
- Purchase Price: $2.10 per share.
- Gross Proceeds: Approximately $10 million (before deducting placement agent fees and offering expenses).
- Closing Date: August 6, 2026.
- Placement Agent: Craig-Hallum Capital Group LLC.
The filing does not provide specific data on revenue, profit, cash flow, margins, debt, or liquidity positions as this report focuses solely on the capital raise event.
Material Changes and Agreements
The Company entered into a Securities Purchase Agreement and a Registration Rights Agreement with institutional and accredited investors. Key terms include:
- Registration Rights: The Company agreed to register the shares for resale, aiming for effectiveness within 60 days if reviewed by the SEC, or 5 business days if not reviewed.
- Lock-up Period: The Company is restricted from issuing new shares, effecting reverse stock splits, or filing new registration statements for 90 days from the Closing Date or 30 days after the registration statement becomes effective, whichever is later.
- Exemptions: Shares were sold under Section 4(a)(2) and Rule 506 of the Securities Act of 1933.
Outlook, Risks, and Management Commentary
Management announced the offering via a press release on August 4, 2026. The filing does not contain specific forward-looking guidance, risk factors, or commentary on the use of proceeds beyond the transaction mechanics. The primary contingency noted is the timeline for the effectiveness of the resale registration statement.
Investor Verification Checklist
- Verify the final net proceeds after deducting placement agent fees and offering expenses.
- Confirm the exact date the resale registration statement is declared effective by the SEC.
- Review the full text of the Securities Purchase Agreement (Exhibit 10.1) for specific covenants and exceptions to the lock-up period.
- Monitor subsequent filings for the use of the $10 million in gross proceeds.